Global Women’s Health Therapeutics Market Size, Share & Trends Analysis Report | Grand View Research Inc

The global Women’s Health Therapeutics Market size is expected to reach USD 210.9 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 8.8% over the forecast period. Entry of effective drugs, a rise in awareness about early diagnosis and treatment, along with prevalence of chronic diseases are among the key factors likely to drive the market during the forecast period.

The women’s health therapeutics market is expected to witness high growth in the forthcoming years due to increasing investment by key market players to fulfill demand in areas of infection, cancer, and pregnancy-related complications. In October 2016, Prelude Fertility, Inc. received USD 200 million from the Reproductive Biology Associates (RBA) and My Egg Bank North America (MEB) that focuses on providing fertility services and treatment to people with delayed childbirth. Juneau Biosciences, LLC has deployed USD 35 million until 2017 towards development of molecular diagnostics and therapeutics for endometriosis (uterus) conditions.

In January 2018, Melinta Therapeutics, Inc. acquired The Medicines Company’s infectious diseases business. This acquisition would help to the former expand its portfolio by offering life-saving treatment options. In November 2017, Biocon launched KRABEVA, a biosimilar used for the treatment of metastatic colorectal, cervical, ovarian, and brain cancer. 

Increasing investments by top market players are anticipated to propel the global market over the forecast period.

There is significant unmet need associated with treatment options for female sexual dysfunction. Currently, there are no Food and Drug Administration (FDA)-approved drugs for the treatment of female sexual dysfunction and many promising molecules are in late stage of development phase. Some of these molecules include LibiGel by BioSante Pharmaceuticals and Femprox by Apricus Bio, currently in Phase III and Phase II of clinical trials respectively in U.S.

Further key findings from the report suggest:

• By type, infection accounted for the largest market share in 2017 and is expected to maintain its dominance during the forecast period due to rising drug approvals, availability of diagnostic tests and treatments, and high incidence of infectious diseases
• Ovarian cancer is anticipated to be the fastest-growing sub-segment of oncology during the forecast period due to high prevalence of ovarian cancer and approval of new and improved drugs
• North America is expected to maintain its dominance in the coming years due to high awareness about women’s health, increase in number of advanced diagnostic and treatment methods, mergers and acquisitions by market players, and rise in infections and cancer cases
• Asia Pacific is likely to witness significant growth over the next decade due to improving healthcare facilities, increase in commercialization and approval of products, and investment by market players
• Some of the key players in women’s health therapeutics market are Bayer AG, Merck & Co., Pfizer, Teva Pharmaceutical Industries Ltd, AstraZeneca, Bristol-Myers Squibb (BMS) Company, Eli Lilly and Company, Novartis AG, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Mylan N.V., Sun Pharmaceutical Industries Ltd, and Sanofi.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/womens-health-therapeutics-market

Veterinary Surgical Instrument Market Insights - Industry Growth and Forecast to 2025

The global Veterinary Surgical Instrument Market size is expected to reach USD 1.33 billion by 2025, according to a new report by Grand View Research, Inc., exhibiting a CAGR of 6.8% during the forecast period. Surging demand for pet adoption is estimated to drive the market during the forecast period. Increasing income in developing countries has also driven the market. For instance, according to a report by the American Veterinary Medical Association, in 2017, around 46.0% household had multiple types of pets in the U.S. 

Furthermore, key players implement strategies such as mergers and acquisitions to sustain in this competitive market. For instance, in 2014, Neogen Corporation acquired SyrVet Incorporated and Prima Tech Incorporated in a probe to expand its product portfolio.

Moreover, technological advancements in surgical devices and availability of a number of detection techniques are anticipated to create growth opportunities for the market. Some of these are micro fracture detection, laparoscopy, and 3D printing. For instance, in October 2016, Surgical Holdings launched reusable surgical instruments for general surgeries in an attempt to cut the cost of the instruments.

Further key findings from the report suggest:

• Handheld devices accounted for the largest revenue share in 2017, owing to their multipurpose use and ease of handling
• On the basis of animal type, the small animal segment is projected to exhibit lucrative growth over the forecast period owing to growing incidence of pet adoption and surging demand for efficient care
• Based on application, the dental surgery segment is poised to dominate the market throughout the forecast period due to increasing prevalence of periodontal diseases and rising demand for pet dental cure
• North America held the dominant position in the global arena in 2017, due to favorable pet insurance policies and new product launch by companies. For instance, in February 2016, DRE Veterinary launched a new radiology unit named DRE Stationary DR X-ray System
• Asia Pacific is anticipated to witness lucrative growth during the forecast period due to rising demand for pet adoption and growing income, especially in Japan and India
• Some of the key companies in the market are Medtronic, DRE Veterinary, B. Braun Vet Care GmbH, and Jorgen Kruuse A/S.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/veterinary-surgical-instruments-market

Global Women's Health Market Size, Trends & Industry Research Report, 2025

The global Women’s Health Market is expected to reach USD 51.3 billion by 2025, according to a new report by Grand View Research, Inc. Increasing female geriatric population, introduction of various drugs related to women’s health, and favorable government policies are some of the factors expected to drive growth during the forecast period.

Women are more prone to certain diseases, such as osteoporosis, osteoarthritis, anemia, menstruation-related disorders, depression, and obesity. Hence, increase in incidence of these conditions is likely to boost the market in the coming years. According to International Osteoporosis Foundation, global prevalence of osteoporosis among women was over 200.0 million in 1990, and this is anticipated to reach 680.0 million in 2050.

Government and various private organizations are working toward improving women’s health across the world, and this is likely to drive growth in the coming years.

Reimbursement coverage provided to women is also a key factor driving the market in developed countries. For instance, various coverage plans in the U.S. provide preventive services for women without charging any copayment. These include screening for anemia, hepatitis B, & breast cancer on a routine basis, folic acid supplements for women who are likely to be pregnant, and contraceptive methods, among others.

Further Key Findings from the Report Suggest:

• Presence of a large female geriatric population, which is susceptible to chronic diseases, is expected to boost growth
• In 2016, postmenopausal osteoporosis accounted for the largest share of the market due to high incidence of osteoporosis in women after menopause, presence of several major players, and cost-effectiveness of this treatment
• Contraceptive segment is likely to witness fastest growth during the forecast period due to increase in awareness and usage, government initiatives, technological developments, and favorable regulatory scenario. For instance, in June 2017, Agile Therapeutics, Inc. resubmitted an NDA for Twirla, an investigational low-dose combined hormonal contraceptive patch
• Geographically, North America held the largest share of more than 30% in 2016 due to presence of major market players, high awareness about regular health check-ups for women, coverage for screening, and increased healthcare expenditure
• Asia Pacific is expected to exhibit fastest growth during the forecast period due to increasing investments by players in the region, rising awareness about women’s health, and initiatives by various governments and private organizations to improve awareness and access to women’s health products
• Some of the key players operating in the women’s health market are Allergan; Bayer AG; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; and Ferring B.V.

Browse Details of Report @ http://www.grandviewresearch.com/industry-analysis/womens-health-market

Hemostasis And Tissue Sealing Agents Market Size, Share & Trends Analysis Report | Grand View Research

The global Hemostasis And Tissue Sealing Agents Market size is expected to reach USD 10.34 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.7% during the forecast period. The agents have gained popularity over time due to their ability to prevent blood loss. Rapid growth of minimal invasive technology and demand for faster recovery by patients is expected to promote market growth over the forecast period.

According to the Centers for Disease Control and Prevention (CDC), approximately 150 million of American population is currently suffering from at least one chronic condition, which leads to surgeries and even mortality at times. An estimate over the rising incidence was made by the CDC, which concluded that over 48% of the entire American population is expected to suffer by chronic condition.

The hemostasis and tissue sealing agents market is expected to witness lucrative growth over the next seven years owing to, an increase in demand supported by rising surgery volumes. Growth in geriatric population and prevalence of chronic conditions are the impact rendering drivers for this industry.

Further key findings from the report suggest:

• The hemostats market is expected to expand at a CAGR of over 8.7% over the forecast period owing to the rise in global volume of surgeries and applicability of the product across a variety of surgeries to avoid occurrence of hypovolemic shock, thrombocytopenia, blood transfusions, and post-operative complications
• Flowable hemostats are a combination of active and mechanical agents. They function by blocking blood flow and also converting fibrinogen into fibrin for coagulation. This segment is expected to witness a lucrative CAGR of over 10.0% from 2018 to 2026
• Some key players operating in the hemostasis and tissue sealing agents market include Johnson & Johnson; CryoLife Inc.; Pfizer; C R Bard; B Braun; Covidien; and Smith & Nephew. Market participants are involved in technological advancements to ensure sustainability and regional presence
• For instance, in March 2015, Ethicon announced higher efficiency of EVARREST fibrin sealant patch as compared to its substitute, TachoSil patch (Baxter). Further study would be conducted at the St. Vincent Heart Centre of Indiana to understand added advantages that the product can offer.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/hemostasis-tissue-sealing-agents-market

Grand View Research has segmented the global hemostasis and tissue sealing agents market on the basis of product and region:

Hemostasis and Tissue Sealing Agents Product Outlook (Revenue, USD Million, 2015 - 2026)

• Topical Hemostat
• Adhesive & tissue sealant

Hemostasis and Tissue Sealing Agents Regional Outlook (Revenue, USD Million, 2015 - 2026)

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Asia Pacific
• China
• Japan
• India
• Thailand
• South Korea
• Latin America
• Mexico
• Brazil
• Argentina
• Colombia
• MEA
• South Africa
• Saudi Arabia
• UAE

Parenteral Nutrition Market Size, Industry Report, 2026 | Grand View Research Inc.

The global Parenteral Nutrition Market size is expected to reach USD 8.26 billion by 2026, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.8% during the forecast period. Increasing rate of natality and surging geriatric population is fueling the market growth.

As of 2014, the natality rate reported by the National Center for Health Statistics (NCHS) is 12.5 births per 1,000 populations in U.S. Furthermore, the percentage of lower weight infants was 8.0%, thereby boosting the demand for parenteral nutrition products in the country. The realized natality is rising over the last decade and is anticipated to sustain growth over the forecast period. However, in 2011, a dip was witnessed in U.S. owing to alteration in fertility rate of the local female population. However, in the same year, hike in the number of births for foreign based immigrant citizens was also observed leading to an overall rise in birth rate.

Moreover, a large number of premature babies suffer from low weight as well as undeveloped immunity thus putting them at risk. Parenteral nutrition reduces the risk of infection and underdevelopment, thereby promoting its application. As per the National Center for Healthcare Statistics, the premature birth rate of the U.S. is about 9.6% as of 2016, and the national authorities are working to reduce it to 8.1%.

In very low birth weight (VLBW) newborns, demand for parenteral nutrition is higher owing to low prospect of enteral nutrition. Hence, use of parenteral nutrition in premature infants results in improved intrauterine nutrient deposition, faster neurological development, and minimized risk of complications thus improving their chances for survival. 

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/parenteral-nutrition-market

Further key findings from the study suggest:

• Single dose amino acid solution segment dominated the market in 2018 owing to increasing use of amino acid solutions that possess fewer side effects thus enhancing patient benefits
• North America led the market in terms of revenue and accounted for 41.73% of the overall share in 2018. Presence of high research expenditure by private entities and government agencies in the healthcare sector and collaborations among medical device industry, regulatory authorities, and universities are responsible for the market growth
• Some of the companies present in the parenteral nutrition market are B. Braun Melsungen AG; Baxter International, Inc.; Fresenius Kabi AG; Hospira, Inc.; Actavis, Inc.; Grifols International S.A.; Otsuka Pharmaceutical Factory, Inc.; and Sichuan Kelun Pharmaceutical Co. Ltd.

Grand View Research has segmented the global parenteral nutrition market based on nutrient type and region:

Parenteral Nutrition Nutrient Type Outlook (Revenue, USD Million, 2015 - 2026)

• Carbohydrates
• Lipid Emulsion
• Single Dose Amino Acid Solution
• Trace Elements
• Vitamins & Minerals

Parenteral Nutrition Regional Outlook (Revenue, USD Million, 2015 – 2026)

• North America
• U.S.
• Canada
• Europe
• U.K.
• Germany
• Spain
• Italy
• France
• Asia Pacific
• Japan
• China
• India
• Thailand
• South Korea
• Latin America
• Brazil
• Argentina
• Mexico
• Colombia
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE

About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: http://www.grandviewresearch.com

Global Antibiotics Market Size, Share & Trends Analysis Report by 2026 | Grand View Research Inc.

The global Antibiotics Market size is expected to reach USD 62.06 billion by 2025 expanding at a CAGR of 4.0%, according to a new report by Grand View Research, Inc. Rising prevalence of infectious diseases, especially in developing regions like Asia Pacific and Middle East, is anticipated to contribute to the market growth. More than 15.0% of the deaths in children below the age of five years, are estimated to be due to pneumonia and according to the statistics provided by the WHO about 9.2 million deaths were recorded in 2015. Similar to tuberculosis, the disease is highly prevalent in the South Asian and Sub-Saharan regions. Currently, the required antibiotic treatment is available only to one-third of the infected population, thereby increasing the disease burden.

Government reforms specific to antibiotics, such as the Generating Antibiotics Incentives Now (GAIN) Act in U.S., are projected to help boost the market growth over the forecast period. This is further expected to facilitate development of advanced drugs. According to an article published by the Pew Charitable Trusts, nearly 30% of the outpatient oral antibiotics prescriptions are unnecessary and majority of these are prescribed for disease conditions, such as non-bacterial infections and acute respiratory conditions, against which antibiotics are not significantly effective. Such indiscriminate use of antibiotics is anticipated to increase the risk of difficult-to-treat antibiotic-resistant infections, thereby increasing the economic burden.

Browse Details Of Report @ https://www.grandviewresearch.com/industry-analysis/antibiotic-market

Further key findings from the study suggest:

• RNA and folic acid synthesis inhibitors are anticipated to witness healthy CAGRs over the forecast period
• Development of several antiviral drugs, which inhibit transcription and reverse transcription process are anticipated to support this growth
• Asia Pacific is anticipated to witness the highest CAGR over the forecast period on account of large population base, prevalence of infectious diseases, regulation reforms, and wide usage of generic medicine
• Latin America, especially Brazil, is also projected to exhibit remunerative growth due to strong growth in pharmaceutical sector
• Outbreak of certain viruses, such as Ebola, in African region contributed to the region’s growth
• Some of the key companies in the market are Pfizer, Inc; Janssen Pharmaceuticals; Abbott laboratories; GlaxoSmithKline plc; Sanofi S.A.; Novartis AG; Bayer AG; Bristol Myers Squibb Company; Eli Lilly & Company, and Astellas Pharma, Inc.

Grand View Research has segmented the global antibiotics market on the basis of action mechanism, drug class, and region:

Antibiotics Action Mechanism Outlook (Revenue, USD Million, 2015 - 2026)

• Cell Wall Synthesis Inhibitors
• Protein Synthesis Inhibitors
• DNA Synthesis Inhibitors
• RNA Synthesis Inhibitors
• Mycolic Acid Inhibitors

Antibiotics Drug Class Outlook (Revenue, USD Million, 2015 - 2026)

• Cephalosporin
• Penicillin
• Fluoroquinolone
• Macrolides
• Carbapenems
• Aminoglycosides
• Sulfonamide
• Other

Antibiotics Regional Outlook (Revenue, USD Million, 2015 - 2026)

• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Asia Pacific
• China
• Japan
• India
• Thailand
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• Colombia
• MEA
• South Africa
• Saudi Arabia
• UAE

About Grand View Research, Inc.:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: http://www.grandviewresearch.com

Pharmaceutical Glass Packaging Market to Grow at a CAGR of 6.3% till 2025 | Grand View Research Inc

The global Pharmaceutical Glass Packaging Market size is expected to reach USD 22.05 billion by 2025, according to a new report by Grand View Research, Inc., registering a CAGR of 6.3% during the forecast period. Spiraling sale of generic drugs in developed as well as developing economies is projected to drive the demand for pharmaceutical glass packaging. Glass has a well-defined supply chain in the pharmaceutical industry and is traditionally used for parenteral drug packaging. Extensive R&D is being conducted by product manufacturers in order to minimize negative aspects of glass, such as high susceptibility to breaking and delamination, as well as to improve the quality & efficacy of the product.

The pharmerging market is anticipated to witness phenomenal growth owing to favorable government policies and increased healthcare awareness. Governments of developing nations are expanding their public or private healthcare coverage and simultaneously making efforts to minimize out-of-pocket medical expenses for the consumers. Increasing government efforts to reduce healthcare cost and promotion of low-cost generic drugs are estimated to fuel the utilization of glass packaging over the coming years.

Emergence of novel drugs such as cancer drugs and bio-therapeutics is likely to help the market gain traction over the coming years. In an effort to safeguard patient health, guidelines for packaging of biological drugs have been made highly stringent, which necessitates constant development in the field of pharmaceutical packaging. Aforementioned factors promote manufacturers to adopt advanced techniques, thereby driving the market.

In primary pharmaceutical packaging, glass has an advantage over plastic as plastic production requires raw materials such as polyethylene, polypropylene, and polystyrene, which are largely dependent on fluctuating petroleum industry. Manufacturers use soda lime, quartz, and other additives for manufacturing glass. These raw materials are easily available in the market by numerous suppliers. Recent developments in the pharmaceutical glass packaging include launch of Gx Baked-On RTF and an Omniflex plunger, a prefilled syringe, by Gerresheimer AG in September 2017. This technology has the ability to minimize particle loads and meet strict requirements for therapeutic protein products for better deliver of drug. 

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/pharmaceutical-glass-packaging-market

Further Key Findings from the Report Suggest:

• The vials segment is projected to ascend at a CAGR of 6.9% in terms of revenue over the forecast period
• The bottles segment dominated the global pharmaceutical glass packaging market in 2016 in terms of revenue and is anticipated to witness a CAGR of 4.7% from 2017 to 2025 owing to high penetration of plastics in the manufacturing of bottles
• The generic drug segment accounted for 69.8% of the market in 2016 due to rapidly increasing manufacturing volumes of generic drugs in emerging economies
• Europe is expected to witness considerable growth during the forecast period owing to constant development in the medical field aimed at improving health and quality of life
• Some of the key companies present in the market are Corning Incorporated; Gerresheimer AG; Nipro Pharmapackaging; SCHOTT AG; Şişecam Group; Arab Pharmaceutical Glass Co.; Beatson Clark; Stevanato Group; and Owens-Illinois, Inc.                                                                                   

Grand View Research has segmented the global pharmaceutical glass packaging market on the basis of product, drug type, and region:

Pharmaceutical Glass Packaging Product Outlook (Revenue, USD Million, 2014 - 2025)

• Vials
• Small vials (<30ml)
• Large vials (>30ml)
• Bottles
• Small Bottles (< 1000 ml)
• Large Bottles (> 1000 ml)
• Cartridges & Syringes
• Ampoules

Pharmaceutical Glass Packaging Drug Type Outlook (Revenue, USD Million, 2014 - 2025)

• Generic
• Branded
• Biologic

Pharmaceutical Glass Packaging Regional Outlook (Revenue, USD Million, 2014 - 2025)

• North America
• U.S.
• Europe
• Germany
• U.K.
• France
• Spain
• Italy
• Asia Pacific
• China
• India
• Japan
• South Korea
• Central & South America
•  Brazil
• Middle East & Africa

Male Infertility Market Size By Test | Industry Report, 2025 | Grand View Research

The global Male Infertility Market is expected to reach USD 4.7 billion by 2025, according to a new report by Grand View Research, Inc. Globally, increasing infertility in male and advancements in diagnostic tests have been major factors driving the market growth. In addition, growing consciousness regarding factors causing male infertility and Assisted Reproductive Technology (ART) has led to increased adoption of treatment.

Furthermore, increasing aging population, rising obesity, and other lifestyle-associated diseases causing infertility are likely to boost the market during the forecast period. In the U.S., one third of infertility cases are due to female factor, one third due to male factors, and remaining one third are unexplained.

DNA fragmentation technique was the largest segment in male infertility tests market in 2016 and is expected to maintain its dominance during the forecast period due to rapid growth in next few years. High cost and increasing adoption in developed countries due to higher sensitivity and reliable analysis of sperm DNA integrity are the key factors for its dominance.

In 2016, ART segment dominated in the treatment market due to high success rate. In Vitro Fertilization and Intracytoplasmic Sperm Injection (ICSI) are the major ARTs used. Medications include corticosteroids and hormonal therapy; however, they are effective in very few cases. Hence, low demand, less adherence, and lower cost as compared to ART are likely to slow the growth of the medication market.

Further Key Findings From the Report Suggest:

• Rising demand of ARTs across the globe is expected to propel growth at the fastest rate from 2017 to 2025
• DNA fragmentation technique for the testing of male infertility dominated in 2016 and is estimated to generate revenue at a rapid rate over the forecast period.
• Oxidative stress analysis is another method gaining popularity due to accurate determination of reactive oxygen species. The test accounted second largest share in the testing market.
• The Europe market was the largest in 2016 and is expected to maintain its dominance during forecast period due to higher awareness, strong diagnosis rate, and high adoption of costlier treatment.
• The industry in Asia Pacific is projected to witness substantial growth over the next decade owing to growing investment by several clinics and pharmaceutical companies in the region, and increasing healthcare expenditure.
• Some key players include EMD Sereno, Inc.; Aytu BioScience, Inc.; Bayer Healthcare; Cadila Healthcare Ltd.; Intas Pharmaceuticals Ltd.; Halotech DNA SL; SCSA diagnostics, Inc.; and Andrology Solutions. However, EMD Sereno, Inc. currently dominates the male infertility market.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/male-infertility-market

Antisense & RNAi Therapeutics Market Size, Industry Report, 2025 | Grand View Research Inc.

The global Antisense And Rnai Therapeutics Market size is expected to reach USD 1.81 billion by 2025, according to a new report by Grand View Research, Inc., recording a 7.5% CAGR during the forecast period. Rising instances of external funding to conduct clinical studies pertaining to introduction of novel drug moieties plays a vital role in the process of new product development. This, along with ongoing developments in biological vectors and nanotechnology, has fueled market growth.

Multinational healthcare establishments promote awareness and aid in finding novel therapies for treatment of different disorders. Private institutes such as California Institute of Regenerative Medicine and ALS Association are involved in conducting trials by funding research institutes and pharmaceutical organizations and this is expected to significantly fuel sector growth. Moreover, government initiatives for speeding the development of drug delivery platforms in order to reduce disease burden are attributive for industrial growth.

Antisense and RNAi therapeutics services are applicable in treatment of a wide range of diseases that target nucleic acid and affect cell growth cycle. miRNA is attracting considerable interest in its ability to restore gene expression and correct protein production, thereby influencing industrial progress. Developments that involve the research of using different routes to deliver the desired effect of candidate moiety before its removal from blood are anticipated to fuel sector growth.

However, challenges associated with drug delivery are expected to impede growth to a certain extent. Delivery technologies that enable mitigation of off-target effects and undesirable immunological stimulation need to be introduced in order to reduce the effect of restraining factors.

Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/global-antisense-and-rni-therapeutic-market

North America Opioid Market Will Reach $18.5 Billion by 2024 | Grand View Research

The North America Opioid Market is expected to reach USD 18.5 billion by 2024, according to a new report by Grand View Research, Inc. Favorable regulations and healthcare reforms are providing an environment, conducive for research and development as well as commercialization efforts directed toward the development of novel abuse-deterrent opioids, to flourish and drive the industry growth during the forecast period. 

Furthermore, the key players are deploying large funds in the development of abuse-deterrent technology wherein drugs are designed to be tamper resistant. This is achieved through alterations involving, among others, the use of physical or chemical barriers to resist convenient extraction of the opioids, the addition of an aversive agent to the formulation that would yield an unpleasant effect upon its extraction, and the formulation of opioid prodrugs that are dependent on enzymatic activity in order to be rendered to their active forms. 

These tamper-resistant opioid drug forms are anticipated to mitigate the incidence of their misuse.

Opioids are the mainstay of chronic pain management that is used to alleviate varied pain conditions. Opiates including codeine and morphine are frequently employed as cough suppression medication. Codeine is considered as a gold standard for cough suppression since it has minimal side effects. Moreover, these narcotics are used in the treatment of irritable bowel syndrome-induced diarrhea since they act on gastrointestinal receptors. In addition, peripherally acting loperamide is commonly used to suppress diarrhea. Thus, the profitable growth of the Opioid Market lies in its breadth of applications in the management of diverse conditions including cough, diarrhea, and pain.

Browse Details of Report@ http://www.grandviewresearch.com/industry-analysis/north-america-opioid-market

Further key findings from the study suggest:

• The extended-release opioids segment accounted for the largest share over 55% in 2015. The dominance of the segment is attributed to the high usage of these drugs for chronic pain management and the development of innovative dosage forms, such as transdermal patches.
• Market share of the immediate-release dosage forms including morphine and codeine, is expected to decline owing to the frequent product recalls and severe side effects associated with their use. The segment is estimated to witness a CAGR of around 1.7% over the forecast period.
• In terms of applications, the pain relief segment held the largest market share in 2015 with a revenue generation of over 9.3 billion. The extensive amount of pain caused during chemotherapy and radiotherapy are the primary factors resulting in the increasing incorporation of these drugs in the cancer segment.
• The post-operative pain management segment is expected to be the fastest growing application in the pain relief category.As a result of their high applicability in post- surgical pain management, the rise in number of surgical procedures is expected to fuel the sectorpenetration of opioids in the near future.
• The U.S. region dominated the global Opioid Market with a sizable revenue share in 2015. One of the major determinants is the growing geriatric population with clinically demonstrated susceptibility to terminal conditions, such as rheumatoid arthritis, is positively impacting this vertical.
• In addition, the increasing adoption of opioids for pain management related to trauma and injury cases, in severe and chronic disabling diseases, and in cases of post-surgical pain, is driving the growth of the market in the North America region
• The Canada regional verticalis expected to witnesssignificant growth over the forecast period with a CAGR of over 5.3% due tothe improvinghealthcare infrastructure and the presence of favorable government reforms governing the use of narcoticsin the treatment of both, acute and chronic pain, as well as in the cases of persistent cough and diarrhea. Additionally, the expanding generic drugs market in this region is expected to provide a potential growth platform for the key players in this vertical.
• Some of the leadingplayers in this verticalinclude Pfizer, Inc., Purdue Pharma L.P., Janssen Pharmaceuticals, Inc., Allergan Plc (Actavis), and Egalet Corporation. Extensive research and development endeavors carried out by companies with the aim of expanding their product pipeline are expected to boost the growth of this sector.

Grand View Research has segmented the North America opioids market on the basis of product, application,and region:

North America Opioid Market, product outlook by revenue (USD Million, 2014 - 2024)

• Immediate - release / Short - acting Opioids
• Codeine
• Oxycodone
• Hydrocodone
• Fentanyl
• Morphine
• Hydroxymorphone
• Oxymorphone
• Propoxyphene
• Other IR opioids
• Extended - release / Long - acting Opioids
• Oxycodone
• Hydrocodone
• Methadone
• Fentanyl
• Morphine
• Oxymorphone
• Tapentadol
• Buprenorphine
• Hydromorphone
• Other ER opioids

North America Opioid Market, application outlook by revenue (USD Million, 2014 - 2024)

• Pain Relief
• Cancer Pain
• Post-operative Pain Management
• Low Back Pain
• Orthopedic
• Neuropathic Pain
• Fibromyalgia
• Anesthesia
• Cough Suppression
• Diarrhea suppression
• De - addiction

North America market, regional outlook by revenue (USD Million, 2014 - 2024)

• U.S.